Reduced CD45 dimerization with increasing expression of CD45-AP
Sample lane* . | HA-CD45AP expression . | CD45 expression . | Dimer-monomer ratio of CD45 . |
|---|---|---|---|
| 1 | 37.2 | 404 | 0.530 ± 0.059 |
| 2 | 32.5 | 392 | 0.583 ± 0.019 |
| 3 | 20.8 | 480 | 0.679 ± 0.030 |
| 4 | 0.0 | 382 | 0.993 ± 0.012 |
| 5 | 0.0 | 484 | 1.17 ± 0.083 |
Sample lane* . | HA-CD45AP expression . | CD45 expression . | Dimer-monomer ratio of CD45 . |
|---|---|---|---|
| 1 | 37.2 | 404 | 0.530 ± 0.059 |
| 2 | 32.5 | 392 | 0.583 ± 0.019 |
| 3 | 20.8 | 480 | 0.679 ± 0.030 |
| 4 | 0.0 | 382 | 0.993 ± 0.012 |
| 5 | 0.0 | 484 | 1.17 ± 0.083 |
The surface expression levels of HA-CD45-AP and CD45 were determined by staining the same ALST-1 transfectants as those described in lanes 1 through 5 of Figure 6 with FITC-conjugated anti-HA or anti-CD45 antibody. The numbers shown are mean fluorescence intensities above background. The dimer-monomer ratios of CD45 were obtained by densitometric analysis of 3 different autoradiograms of Figure 6A. Regions scanned for monomer and dimer quantification are indicated in Figure 6A. Data are expressed as an arithmetic mean ± SD.
Lanes are those shown in Figure 6A.